Conjugated linoleic acid supplementation enhances antihypertensive effect of ramipril in chinese patients with obesity-related hypertension

American Journal of Hypertension

Volumn 22, Issue 6, 2009, Pages 680-686

  Zhao, Wen Sheng ^a   Zhai, Jia Jie ^a   Wang, Yi Hui ^a   Xie, Pa Sha ^a   Yin, Xiao Jing ^a   Li, Long Xue ^a   Cheng, Kang Lin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSINOGEN; CONJUGATED LINOLEIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RAMIPRIL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; ESSENTIAL HYPERTENSION; FATTY ACID BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADIPONECTIN; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; BLOOD PRESSURE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LEPTIN; LINOLEIC ACIDS, CONJUGATED; MALE; MIDDLE AGED; OBESITY; RAMIPRIL; TREATMENT OUTCOME;

EID: 67349103828     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.56     Document Type: Article

References (35)

1. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia. A link between hypertension, obesity and glucose tolerance. J Clin Invest 1985; 75:809-817.
2. Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu Rev Nutr 2002; 22:505-531.
3. Pariza MW, Park Y, Cook ME. The biologically active isomers of conjugated linoleic acid. Prog Lipid Res 2001; 40:283-298.
4. Liew C, Schut HA, Chin SF, Pariza MW, Dashwood RH. Protection of conjugated linoleic acids against 2-amino-3-methylimidazo(4,5-f )quinoline-induced colon carcinogenesis in the F344 rat: a study of inhibitory mechanisms. Carcinogenesis 1995; 16:3037-3043.
5. Ryder JW, Portocarrero C P, Song XM, Cui L, Yu M, Combatsiaris T, Galuska D, Bauman DE, Barbano DM, Charron MJ, Zierath JR, Houseknecht KL. Isomer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 2001; 50:1149-1157.
6. Park Y, Albright KJ, Liu W, Storkson JM, Cook ME, Pariza MW. Effect of conjugated linoleic acid on body composition in mice. Lipids 1997; 32:853-858.
7. Raff MTT, Tholstrup T, Sejrsen K, Straarup EM, Wiinberg N. Diets rich in conjugated linoleic acid and vaccenic acid have no effect on blood pressure and isobaric arterial elasticity in healthy young men. J Nutr 2006; 136:992-997.
8. Herrera JA, Arévalo-Herrera M, Shahabuddin AK, Ersheng G, Herrera S, Garcia RG, López-Jaramillo P. Calcium and conjugated linoleic acid reduces pregnancy-induced hypertension and decreases intracellular calcium in lymphocytes. Am J Hypertens 2006; 19:381-387.
9. Nagao K, Inoue N, Wang YM, Yanagita T. Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats. Biochem Biophys Res Commun 2003; 310: 562-566.
10. Nagao K, Inoue N, Wang YM, Hirata J, Shimada Y, Nagao T, Matsui T, Yanagita T. The 10trans,12cis isomer of conjugated linoleic acid suppresses the development of hypertension in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun 2003; 306:134-138.
11. Matsuo T, Yagi K. Interaction between α-linolenic acid-enriched oil and ACE inhibitor concerning the decrease in blood pressure in SHR. J Oleo Sci 2008; 57:11-14.
12. Inoue N, Nagao K, Hirata J, Wang Y, Yanagita T. Conjugated linoleic acid prevents the development of essential hypertension in spontaneously hypertensive rats. Biochem Biophys Res Commun 2004; 323:679-684.
13. Redon J. Hypertension in obesity. Nutr Metab Cardiovasc Dis 2001; 11:344-353.
14. Verdecchia P, Angeli F. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
15. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey L P, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336:1117-1124.
16. Korhonen M, Kastarinen M, Uusitupa M, Puska P, Nissinen A. The effect of intensified diet counseling on the diet of hypertensive subjects in primary health care: a 2-year open randomized controlled trial of lifestyle intervention against hypertension in eastern Finland. Prev Med 2003; 36:8-16.
17. Harrington KE, Robson PJ, Kiely M, Livingstone MB, Lambe J, Gibney MJ. The North/South Ireland Food Consumption Survey: survey design and methodology. Public Health Nutr 2001; 4:1037-1042.
18. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226:497-509.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
20. Meng QC, Balcells E, Dell'Italia L, Durand J, Oparil S. Sensitive method for quantitation of angiotensin-converting enzyme (ACE) activity in tissue. Biochem Pharmacol 1995; 50:1445-1450.
21. Juan CC, Au LC, Fang VS, Kang SF, Ko YH, Kuo SF, Hsu Y P, Kwok CF, Ho LT. Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 2001; 289:1328-1333.
22. Smedman A, Vessby B. Conjugated linoleic acid supplementation in humans - metabolic effects. Lipids 2001; 36:773-781.
23. Blankson H, Stakkstad J, Fagertun H, Thorn E, Wadstein J, Gudmundson O. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr 2000; 130:2943-2948.
24. Thom E, Wadstein J, Gudmundson O. Conjugated linoleic acid reduces body fat in healthy exercising humans. J Int Med Res 2001; 29:392-396.
25. Mougios V, Matsakas A, Petridou A, Ring S, Sagredos A, Melissopoulou A, Tsigilis N, Nikolaidis M. Effect of supplementation with conjugated linoleic acid on human serum lipids and body fat. J Nutr Biochem 2001; 12:585-594.
26. Zambell KL, Keim NL, Van Loan MD, Gale B, Benito P, Kelley D, Nelson GJ. Conjugated linoleic acid supplementation in humans: effects on body composition and energy expenditure. Lipids 2000; 35:777-782.
27. Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and lipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol 2003; 91:20C-23C.
28. Noone E, Roche HM, Nugent A P, Gibney MJ. The effect of dietary supplementation using isomeric blends of conjugated linoleic acid on lipid metabolism in healthy human subjects. Br J Nutr 2002; 88:243-251.
29. Risérus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans 10cis 12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. Diabetes Care 2002; 25:1516-1521.
30. López-Jaramillo P, Silva SY, Rodríguez-Salamanca N, Duràn A, Mosquera W, Castillo V. Are nutrition-induced epigenetic changes the link between socioeconomic pathology and cardiovascular diseases?. Am J Ther 2008; 15:362-372.
31. Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, Shimamoto K. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997;10 Pt 1:1171-1174.
32. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence?. J Hypertens 2001; 19:667-674.
33. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633.
34. Rueda-Clausen CF, Lahera V, Calderón J, Bolivar IC, Castillo VR, Gutiérrez M, Carreño M, Oubiña MD, Cachofeiro V, López-Jaramillo P. The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. Int J Cardiol 2008; e-pub ahead of print 13 October 2008.
35. Matsui T, Li CH, Tanaka T, Maki T, Osajima Y, Matsumoto K. Depressor effect of wheat germ hydrolysate and its novel angiotensin I-converting enzyme inhibitory peptide, Ile-Val-Tyr, and the metabolism in rat and human plasma. Biol Pharm Bull 2001; 23:427-431.